艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

盘前交易 07-31 07:35:32 EDT

78.41

-1.98

-2.46%

盘前78.66

+0.51+0.66%

07:15 EDT

最高80.21	最低77.35	成交量120.93万
今开80.05	昨收80.39	日振幅3.55%
总市值94.11亿	流通市值94.11亿	总股本1.20亿
成交额9,439万	换手率1.01%	流通股本1.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":78.41,"timestamp":1785441600000,"preClose":80.39,"halted":0,"volume":1209336,"hourTrading":{"tag":"盘前","latestPrice":78.6564,"preClose":78.143,"latestTime":"07:15 EDT","volume":83,"amount":6534.98176,"timestamp":1785496542455,"change":0.5134,"changeRate":0.00657,"amplitude":0.017194},"delay":0,"changeRate":-0.024629929095658712,"floatShares":120028300,"shares":120028300,"eps":1.85165,"marketStatus":"盘前交易","change":-1.98,"latestTime":"07-31 07:35:32 EDT","open":80.05,"high":80.205,"low":77.35,"amount":94387931.05836,"amplitude":0.035514,"askPrice":86.84,"askSize":100,"bidPrice":78.1,"bidSize":8,"shortable":3,"etf":0,"ttmEps":1.85165,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785504600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":78.143,"dividendRate":0.039638,"preHourTrading":{"tag":"盘前","latestPrice":78.6564,"preClose":78.143,"latestTime":"07:15 EDT","volume":83,"amount":6534.98176,"timestamp":1785496542455,"change":0.5134,"changeRate":0.00657,"amplitude":0.017194},"postHourTrading":{"tag":"盘后","latestPrice":79.2,"preClose":78.41,"latestTime":"19:34 EDT","volume":37062,"amount":2906382.108,"timestamp":1785454451791,"change":0.79,"changeRate":0.010075,"amplitude":0.020278},"volumeRatio":0.8606029776475628,"impliedVol":0.2111,"impliedVolPercentile":0.312},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2655280547","title":"李氏大药厂：专有ADC项目ZK2401新药临床试验申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655280547","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655280547?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:20","pubTimestamp":1785421250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ADC","BK4231","PSYK","NETL","IBBJ","MDTX","BMED","IBBQ","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655712728","title":"科伦药业(002422.SZ)：TROP2 ADC芦康沙妥珠单抗(sac-TMT)新增适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655712728","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655712728?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:31","pubTimestamp":1785411100,"startTime":"0","endTime":"0","summary":"此前，芦康沙妥珠单抗用于一线治疗不可手术切除的局部晚期、复发或转移性PD-L1阴性TNBC已获NMPA授予突破性疗法认定。本次新增适应症上市申请亦已纳入优先审评审批程序，成为芦康沙妥珠单抗纳入该程序的第六项上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","NETL","002422","BK4080","BK0060","LU1934453819.USD","LU2148510915.USD","BK4231","IPOS","LU1979443071.USD","ADC","LU1064131003.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654395072","title":"Sonesitatug vedotin 在 CLDN18.2阳性晚期胃癌/胃食管结合部癌的二线及后线治疗中，显示出具有统计学显著性且重要临床意义的总生存期（OS）改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2654395072","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654395072?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:18","pubTimestamp":1785212280,"startTime":"0","endTime":"0","summary":"关于胃癌和胃食管结合部癌 胃癌是全球第五大常见癌症，也是癌症相关死亡的第五大原因。关键次要终点为二线及后线治疗人群的总生存期。CLDN18.2是一种存在于胃黏膜上皮中的蛋白，已被验证为肿瘤治疗领域的重要治疗靶点，尤其在胃肠道肿瘤中具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BTCW","YBTC","BTRN","HODL","EZBC","IBBQ","BTCO","CBOJ","QBF","BETE","BTCL","BETH","CBTJ","MNRS","ADC","BTCZ","CBXO","IBIT","IHC","SBIT","CBTY","PFS","NETL","CBTO","FBTC","BITX","BRRR","DEFI","ARKB","CBTA","CBXY","XBTY","AZN","HCC","BITI","CBXJ","AZNH","CBXA","BTCI","BTC","BITU","EAC","BFJL","BTFX","BCCC","MAXI","CBOA","COAL","BITY","BITO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045277","title":"科伦药业(002422.SZ)：科伦博泰新型双载荷ADC药物SKB565新药临床试验(IND)申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654045277?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:16","pubTimestamp":1785161788,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ADC","BK4231","IND","PSYK","BK4080","NETL","IBBQ","MDTX","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654936970","title":"英派药业首个双载荷ADC成果落地：IMP3201被提名为临床前候选化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=2654936970","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654936970?lang=zh_cn&edition=full","pubTime":"2026-07-27 09:06","pubTimestamp":1785114360,"startTime":"0","endTime":"0","summary":"7月27日，英派药业（07630）发布公告，宣布IMP3201被提名为临床前候选化合物（PCC），这是基于公司自主研发的双载荷ADC平台的首个成果。IMP3201是一种靶向CEACAM5的双载荷ADC，采用优化的摩尔比搭载Exatecan及公司专有的ATR抑制剂。该化合物旨在治疗胃肠道恶性肿瘤，包括结直肠癌、胰腺癌、胃癌及食管鳞状细胞癌，以满足临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273821349058.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273821349058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4231","BK4080","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654639210","title":"百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654639210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654639210?lang=zh_cn&edition=full","pubTime":"2026-07-26 15:48","pubTimestamp":1785052138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的创新生物药注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中对比T-Bren与医生选择的化疗的III期随机对照临床试验已于近日完成首例受试者入组。据悉，T-Bren是一种靶向HER2的创新型ADC，具有同类最佳潜力，已在临床试验中展示出显著的抗肿瘤功效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","NETL","BK4231","ADC","91194","PSYK","688506","BK4080","IBBJ","BK0239","02615","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131761114","title":"财报前瞻｜艾格里房产本季营收预计增18.08%，租金收入支撑增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1131761114","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131761114?lang=zh_cn&edition=full","pubTime":"2026-07-23 14:04","pubTimestamp":1784786674,"startTime":"0","endTime":"0","summary":"艾格里房产预计于2026年07月30日盘后发布财报，市场关注本季营收与盈利韧性及股息延续所带来的估值稳定性。市场一致预期本季度艾格里房产营收约为2.02亿美元，同比增长18.08%；调整后每股收益约为0.47美元，同比增长4.85%；息税前利润约为1.03亿美元，同比增长14.35%。目前未见明确披露的本季度毛利率、净利率或净利润的量化预测数据，故不予展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜艾格里房产本季营收预计增18.08%，租金收入支撑增长","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653221532","title":"【券商聚焦】中国银河证券首予映恩生物(09606)推荐评级 指其ADC管线梯队完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2653221532","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653221532?lang=zh_cn&edition=full","pubTime":"2026-07-21 15:31","pubTimestamp":1784619085,"startTime":"0","endTime":"0","summary":"DB-1303安全性可控，HER2阳性乳腺癌已递交上市申请，填补HER2低表达患者治疗空白。DB-1310针对EGFR靶向耐药肺癌，多线人群ORR达43.5%。DB-1305联合双抗一线三阴性乳腺癌确认超高缓解率。创新管线中，全球首创自免ADC DB-2304靶向BDCA2，直击红斑狼疮未满足临床需求，已推进至IIa期。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","09606","601881","161027","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652903211","title":"Biohaven将在ESMO大会公布BHV-1530 ADC新药临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2652903211","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652903211?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:25","pubTimestamp":1784557500,"startTime":"0","endTime":"0","summary":"生物制药公司Biohaven周一宣布，将在即将举行的欧洲肿瘤内科学会大会上公布其新型FGFR3靶向抗体偶联药物BHV-1530的临床数据。BHV-1530搭载了公司专有的拓扑异构酶I抑制剂有效载荷。　　Biohaven在新闻稿中表示，此次公布的数据将包括BHV-1530在晚期实体瘤患者中的首次人体临床试验初步结果，重点评估药物的安全性、耐受性和初步抗肿瘤活性。Biohaven的BHV-1530数据将在大会的“新药物”专题环节中以口头报告形式呈现。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-20/doc-iniinmvy8222546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BHV","ADC","NETL","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651436406","title":"科伦药业：TROP2 ADC联合疗法肺癌3期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651436406","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651436406?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:58","pubTimestamp":1784087937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NETL","BK4080","BK4231","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650906760","title":"港股异动 | 百奥赛图-B(02315)涨超14% 近日与Whitehawk达成全球合作 共同开发创新双特异性抗体ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2650906760","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650906760?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:10","pubTimestamp":1783653039,"startTime":"0","endTime":"0","summary":"根据协议，百奥赛图将通过其自主研发的RenLite平台提供至多五款全人双特异性抗体，Whitehawk将结合其ADC连接子-载荷平台技术对这些抗体进行评估。Whitehawk随后可选择将由此产生的BsADC候选分子纳入其管线并推进开发。通过整合百奥赛图与Whitehawk的互补优势，本次合作旨在发掘具有差异化靶向机制和治疗潜力的BsADC候选分子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","BK4231","BK4588","NETL","VXUS","KCAI","ADC","BK4080","02315","BK0216","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649137647","title":"从“旁观者”到“追赶者”：诺华(NVS.US)斥资15亿美元收购Myricx，ADC赛道再落关键一子","url":"https://stock-news.laohu8.com/highlight/detail?id=2649137647","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649137647?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:02","pubTimestamp":1783328521,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华已就收购英国生物技术企业Myricx Bio达成协议，交易总对价最高可达15亿美元。据诺华周一发布声明，Myricx股东将获得11亿美元预付款，以及最高4亿美元的潜在里程碑付款。2025年10月，诺华以120亿美元收购了Avidity Biosciences，成为当年规模最大的抗体相关交易。此次收购Myricx，正是其深耕肿瘤学核心领域、充实ADC管线的关键落子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4578","PPH","NVS","LU0320765489.SGD","BK4585","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","NETL","LU0070302665.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","ADC","IE00BJT1NW94.SGD","MEDX","LU0211331839.USD","BK4231","IE0002141913.USD","LU0208291251.USD","IE0009355771.USD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649461757","title":"诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649461757","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649461757?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:52","pubTimestamp":1783302720,"startTime":"0","endTime":"0","summary":"　　诺诚健华盘中涨超9%，截至发稿，股价上涨6.42%，现报13.92港元，成交额5426.90万港元。　　7月6日，据诺诚健华官微消息，公司宣布自主研发的靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药。基于诺诚健华自主研发的ADC技术平台，ICP-208由人源化抗CDH17抗体通过蛋白酶可裂解连接子与公司自主开发的强效有效载荷偶联而成，可精准靶向肿瘤细胞，同时最大限度减少脱靶效应。目前，全球尚无CDH17靶向ADC新药上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-06/doc-inifvqsf1795989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","ADC","IBBQ","BK4231","06978","BK1161","BK1574","NETL","BK0239","09969","159992","BK4080","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648630681","title":"博腾双载荷ADC IND成功交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2648630681","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648630681?lang=zh_cn&edition=full","pubTime":"2026-07-03 11:05","pubTimestamp":1783047950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IND","ADC","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648980686","title":"芯海科技：性能参数方面，功耗、安全、软件生态、ADC精度、主频均处于行业领先水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2648980686","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648980686?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:01","pubTimestamp":1783000860,"startTime":"0","endTime":"0","summary":"证券日报网7月2日讯，芯海科技在接受调研者提问时表示，性能参数方面，功耗、安全、软件生态、ADC精度、主频均处于行业领先水平。例如，传统EC主频通常为9.6兆，公司产品为百兆主频，除基础功能外可承担管理中枢作用，还具备AI相关能力；公司是全球首个联合联想发布基于Zephyr操作系统EC的厂商；公司推行IPD集成产品开发体系，保障产品高成熟度，是半导体行业为数不多横跨消费、工业、汽车三大领域的企业，产品已通过消费级、工业级、车规级相关品牌客户的认证。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-02/doc-inifmrts2638484.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-02/doc-inifmrts2638484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4080","ADC","BK4231","BK4585","VGT","688595","159180","BK0214"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504319","title":"石药集团：自主研发ADC药物SYS6043获纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504319","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648504319?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:57","pubTimestamp":1782989820,"startTime":"0","endTime":"0","summary":"南财智讯7月2日电，石药集团（01093.HK）发布自愿公告，公司自主研发的靶向B7-H3人源化单克隆抗体偶联药物SYS6043，已获国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为单药治疗铂耐药卵巢癌、原发性腹膜癌及输卵管癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607023792065330.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023792065330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B5MMRT66.SGD","HK0000165453.HKD","LU1813983027.USD","ADC","LU1226287529.USD","IE00BZ08YT58.USD","LU0880133367.SGD","01093","LU0140636845.USD","LU0072913022.USD","BK1191","BK4080","LU1152091168.USD","LU1328277881.USD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","LU2039709279.SGD","LU1993786604.SGD","LU1226288170.HKD","BK4231","LU0326950275.SGD","LU1226288253.USD","LU0501845795.SGD","LU0314109678.HKD","LU0067412154.USD","LU1951186391.HKD","LU1008478684.HKD","BK1521","IE0008369823.USD","IE0008368742.USD","IE00BZ08YS42.EUR","IE00B031HY20.USD","LU1960683339.HKD","LU0315179316.USD","BK1515","LU1152091754.HKD","SG9999004220.SGD","LU1226287875.USD","LU1226287792.SGD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647801385","title":"双抗ADC新药宜泽康®在蓉首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2647801385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647801385?lang=zh_cn&edition=full","pubTime":"2026-06-30 14:56","pubTimestamp":1782802595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4080","ADC","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647358924","title":"【券商聚焦】国金证券：创新药企业扭亏节点已至 持续关注小核酸、双抗、ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2647358924","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647358924?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:13","pubTimestamp":1782789198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。具体布局思路而言：(1)布局业绩财报窗口期，掘金业绩超预期标的；(2)关注学会大会动态，把握重磅临床数据发布窗口；(3)聚焦核心赛道，持续关注小核酸、双抗、ADC等相关标的的投资机会。风险提示：汇兑风险、投融资周期波动风险、并购整合不及预期的风险、数据安全与隐私合规风险等。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984822","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK0276","BK0183","ADC","BK0188","BK0028","BK4231","600109","BK1161","BK4080","BK0012","06978","BK0201","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645294190","title":"全球首个获批双抗ADC上市，百利天恒(688506.SH)加速向MNC跨代跃迁","url":"https://stock-news.laohu8.com/highlight/detail?id=2645294190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645294190?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:01","pubTimestamp":1782126096,"startTime":"0","endTime":"0","summary":"作为全球首创EGFR×HER3双抗ADC，百利天恒的1类新药宜泽康在国内获批上市，用于复发/转移性鼻咽癌后线治疗。6月22日，百利天恒发布的这则重磅公告，引发了市场的广泛关注。本次获批，也标志着肿瘤治疗正式迈入双抗ADC新时代。此次在国内获批上市，是宜泽康加速成为“下一代基石癌症疗法”的第一步。该药由此成为全球第二款迈入III期临床开发的DLL3 ADC药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","ADC","91194","688506","IPOS","BK4231","02615","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642250194","title":"港股异动 | 君实生物(01877)涨超5% 近日拟入股上海致域生物医药 布局ADC与多特异抗体研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2642250194","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642250194?lang=zh_cn&edition=full","pubTime":"2026-06-12 15:07","pubTimestamp":1781248026,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物涨超5%，截至发稿，涨4.67%，报17.26港元，成交额6560.03万港元。消息面上，近日，君实生物发布公告，公司拟与苏州众合、君实工程、苏州君盟、合资公司上海致域生物医药有限公司及姚盛博士订立合资协议，据此，转让方有条件同意向合资公司授予许可知识产权的一项许可，用于许可产品的研究、开发、制造、使用及商业化；向合资公司转让有形资产；及向合资公司转让IP权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XBI","BK1161","BK4585","BK4231","BK4581","BK1583","BK4588","BK1515","VXUS","399441","ADC","BK4080","161726","01877"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":0.0353},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0856},{"period":"1year","weight":0.0756},{"period":"ytd","weight":0.0886}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003579},{"month":2,"riseRate":0.46875,"avgChangeRate":0.002186},{"month":3,"riseRate":0.5625,"avgChangeRate":0.012831},{"month":4,"riseRate":0.59375,"avgChangeRate":0.003425},{"month":5,"riseRate":0.484848,"avgChangeRate":0.013996},{"month":6,"riseRate":0.666667,"avgChangeRate":0.010466},{"month":7,"riseRate":0.666667,"avgChangeRate":0.023221},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}